U.S. Short Peripheral Intravenous Catheters Market: $3.42B

Market Outlook

By 2032, the U.S. Short Peripheral Intravenous Catheters Market is projected to reach approximately USD 3.42 billion, expanding at a compound annual growth rate of 7.39% across the forecast period from 2027 to 2032. The market achieved a valuation of USD 2.23 billion in 2026, building upon historical benchmarks of USD 1.82 billion in 2023, USD 1.94 billion in 2024, and USD 2.08 billion in 2025. All monetary metrics within this clinical and economic evaluation are delineated in USD billions.

The short peripheral intravenous catheter industry represents the foundational backbone of American acute inpatient medicine, surgical care, emergency resuscitation, and outpatient infusion therapy. Vascular access via a short peripheral intravenous catheter is the single most common invasive clinical procedure performed in modern healthcare. Between 70% and 90% of all patients admitted to United States hospitals require peripheral venous access during their inpatient encounter. This clinical ubiquity translates into an annual placement volume exceeding 330 million short peripheral IV catheters across American health systems, ambulatory surgery centers, and emergency medical networks.

Despite its foundational status in clinical practice, vascular access management faces substantial operational friction and clinical complications. Historical clinical observation across multi-center United States hospital cohorts reveals that first-time insertion failure occurs in 20% to 40% of standard patient encounters, surging past 50% in patients presenting with difficult vascular access. Factors driving difficult vascular access include advanced age, chronic kidney disease, severe obesity, diabetes, chemotherapy-induced venous sclerosis, sickle cell disease, and a history of intravenous substance use. Premature catheter failure occurs in 35% to 50% of placed catheters prior to the planned completion of therapy. This premature failure is triggered by mechanical phlebitis, local extravasation, accidental dislodgement, lumen occlusion, hematoma formation, and localized venous thrombophlebitis.

The clinical and economic fallout of catheter failure is driving an institutional transformation in vascular access device selection. Health systems are aggressively departing from low-cost, open-system conventional safety catheters in favor of fully integrated, closed-system catheter platforms equipped with multi-access blood-control septums, advanced polyurethane biomaterials, and integrated stabilization mechanisms. While an open conventional catheter carries a lower purchase price, its total cost of care is magnified by accessory extension sets, standalone securement devices, secondary venipuncture supplies, nursing labor expenditure, and the clinical costs of managing cutaneous blood exposure or peripheral line-associated complications.

The historical market trajectory from 2023 to 2025 reflected post-pandemic surgical volume normalization, enterprise hospital inventory stabilization, and an accelerating operational pivot toward occupational bloodborne pathogen containment under OSHA standards. From 2027 through 2032, market expansion will be governed by demographic shifts among Medicare-eligible populations, the expansion of ambulatory surgical centers, heightened institutional focus on peripheral line-associated bloodstream infections, and the commercial adoption of all-in-one closed catheter architectures that support extended dwell times, integrated blood collection, and blood exposure containment.

Introduction

According to the U.S. Short Peripheral Intravenous Catheters Market Report, short peripheral intravenous catheters occupy a critical position within hospital operations, bridging basic fluid management with advanced pharmacotherapy and hemodynamic monitoring. A hospitalized adult frequently requires peripheral venous cannulation immediately upon entry through the emergency department, utilizes that access for intravenous contrast administration in diagnostic imaging, relies on it during perioperative anesthesia, and maintains it on medical-surgical floors for continuous hydration, antibiotic administration, analgesia, and electrolyte replacement. This systemic reliance makes the peripheral catheter an indispensable recurring consumable that dictates day-to-day nursing workflow, bedside efficiency, and patient clinical safety.

Integrated and closed-system peripheral intravenous catheters represent the dominant revenue engine of the modern market, commanding approximately 57.4% of total U.S. catheter expenditure in 2026. These platforms combine an over-the-needle safety catheter with pre-assembled extension tubing, passive needle-shielding mechanisms, integrated stabilization platforms, and multi-access blood-control septums that prevent blood reflux during cannulation and subsequent hub manipulation. The economic transition toward integrated systems is supported by clear clinical evidence: by eliminating the need for clinicians to manually connect extension sets and manually compress veins to prevent blood spillage, integrated systems reduce the risk of touch contamination, micro-motion within the vein, and occupational blood exposure.

Hospitals and integrated delivery networks constitute the primary purchasing channel, consuming approximately 71.3% of total peripheral intravenous catheter volume and revenue across the United States. Inpatient hospital procurement is managed through group purchasing organization contracts, enterprise value-analysis committees, and system-wide vascular access standardization initiatives. Acute care buyers are moving beyond acquisition unit costs to evaluate catheter performance across total dwell integrity, insertion attempt frequency, nurse satisfaction, sharps safety compliance, and complication mitigation.

The economic realities of the bedside nursing shortage across American hospitals have intensified the demand for devices that deliver high first-stick success and extended functional longevity. With average registered nurse turnover rates remaining high across acute care facilities, the institutional cost of nurses performing multiple venipuncture attempts is unsustainable. Each failed insertion attempt consumes between 15 and 30 minutes of clinical labor and approximately USD 28 to USD 45 in wasted disposable supplies, while simultaneously consuming viable peripheral veins and elevating patient dissatisfaction. Health-system CFOs and chief nursing officers are standardizing vascular access products around catheters that protect peripheral venous capital and remain patent for the duration of therapy.

Regulatory frameworks have permanently altered catheter manufacturing and procurement. The Occupational Safety and Health Administration Bloodborne Pathogens Standard, reinforced by the federal Needlestick Safety and Prevention Act, mandates that healthcare institutions implement safety-engineered medical devices to minimize sharps injuries. Non-safety catheters have been relegated to specialized, negligible applications in the United States, representing less than 4% of total market revenue in 2026. Current clinical and regulatory attention is shifting toward the occupational hazard of muco-cutaneous blood exposure during peripheral catheter placement, creating institutional preference for multi-access blood-control technologies that contain blood without requiring manual digital pressure.

Clinical practice guidelines established by the Infusion Nurses Society have fundamentally changed the timing of catheter replacement. Historical paradigms mandated routine, time-based catheter replacement every 72 to 96 hours to minimize infection and thrombophlebitis. Current evidence-based guidelines advocate for replacing peripheral catheters only when clinically indicated—meaning a catheter should remain in situ until therapy is completed or a definitive complication arises. This clinical shift has created an imperative for advanced biomaterials, such as specialized polyurethanes that soften inside the vein to minimize intraluminal mechanical friction, thereby supporting prolonged dwell times exceeding 5 to 7 days without triggering endothelial trauma.

Between 2027 and 2032, market dominance will belong to catheter manufacturers that align vascular access devices with enterprise clinical workflow automation, ultrasound-guided deep vein vascular access, needle-free blood specimen collection from indwelling peripheral lines, and infection control protocols. The market is transitioning from simple disposable plastics into clinically validated, engineered vascular access systems that safeguard nursing personnel, protect fragile patient vasculature, and lower the enterprise cost of intravenous delivery.

Key Market Drivers: What’s Fueling the U.S. Short Peripheral Intravenous Catheters Market Boom?

The primary driver propelling the market is the massive scale of annual hospital admissions and emergency department visits requiring immediate vascular access. With more than 33 million annual inpatient hospital admissions and over 140 million emergency department presentations across the United States, peripheral intravenous catheterization is performed at an industrial scale. The continuous growth of an aging, multi-morbid American demographic guarantees sustained utilization of acute medical-surgical beds, where intravenous fluid delivery, targeted antibiotic therapies, and emergency medication infusions remain non-negotiable standards of care.

A secondary driver is the widespread clinical transition from arbitrary time-based catheter restarts to clinically indicated removal protocols. Under updated guidance from the Infusion Nurses Society and the Centers for Disease Control and Prevention, hospitals are replacing catheters based on objective clinical indicators—such as localized pain, redness, swelling, extravasation, or occlusion—rather than automatically removing functional lines at 72 or 96 hours. This transition demands high-durability catheters fabricated from advanced thermo-softening polyurethane biomaterials that maintain patency, resist internal thrombus aggregation, and minimize vascular irritation over extended dwell durations of 5 to 7 days. Because fewer catheters are consumed per patient encounter under this protocol, health systems are actively reallocating consumable budgets toward premium, higher-margin integrated closed catheters that guarantee structural dwell integrity.

A third driver is the growing clinical challenge of difficult vascular access within the inpatient population. Over 35% of adult medical-surgical inpatients in the United States present with clinical characteristics that complicate peripheral venous cannulation, including morbid obesity, chronic renal failure, severe peripheral vascular disease, prolonged intravenous chemotherapy, and scarring from previous repetitive venipunctures. Patients with difficult vascular access endure multiple painful placement attempts, delayed clinical therapies, and avoidable escalations to invasive central venous catheters or peripherally inserted central catheters. To overcome this challenge, health systems are investing in specialized short peripheral catheters engineered with echogenic needle tips for ultrasound guidance, thin-walled designs that yield high volumetric flow rates through smaller gauges, and advanced tip geometries that facilitate smooth vein entry.

A fourth driver is the enforcement of workplace safety standards governing bloodborne pathogen transmission and mucocutaneous blood contact. While safety-engineered needle-shielding mechanisms are universal across American hospitals, clinical studies demonstrate that clinicians experience cutaneous blood contact in up to 38% of traditional open-system catheter insertions. Blood leakage onto bedding, floor surfaces, and healthcare provider gloves during needle extraction creates biological hazard risks and escalates room turnover costs. The widespread adoption of internal multi-access blood-control septum valves, which mechanically seal the catheter hub against blood escape until an intravenous line or blood-draw adapter is attached, has emerged as an infection control and occupational safety priority for hospital procurement teams.

A fifth driver is the institutional migration toward integrated, closed vascular access systems that consolidate multiple procedural steps into a pre-assembled sterile device. Traditional open catheter insertion requires the nurse to open and connect multiple separate SKUs, including an extension set, a needle-free connector, and an external stabilization device. Each mechanical junction introduces contamination risks and increases insertion time. Integrated systems combine the catheter, extension tubing, stabilization wings, and blood-control valves into a single closed unit. By eliminating manipulation at the catheter hub and decreasing micro-motion against the vein wall, integrated systems reduce complication rates, lower overall supply chain procurement complexity, and conserve nursing time.

A sixth driver is the rapid procedural expansion of ambulatory surgery centers and specialized outpatient clinics. Driven by commercial payer policies and Medicare reimbursement shifts, millions of elective orthopedic, cardiovascular, general surgical, and ophthalmic procedures have moved from acute hospital operating rooms into outpatient surgical facilities. Ambulatory surgical environments demand rapid, reliable, first-stick vascular access solutions that allow efficient surgical prep, stable intraoperative anesthesia infusion, and swift postoperative recovery. Outpatient oncology infusion suites and ambulatory gastroenterology centers similarly demand dependable peripheral access devices that minimize extravasation risks during the administration of high-cost vesicant antineoplastics and biologics.

A seventh driver is the financial pressure exerted on hospitals by federal value-based purchasing frameworks and hospital-acquired condition penalty programs. While central line-associated bloodstream infections have historically dominated institutional surveillance, hospital leadership and regulatory bodies are placing increased scrutiny on peripheral line-associated bloodstream infections. Given that hundreds of millions of peripheral catheters are placed annually, even low infection incidence rates yield thousands of avoidable, costly bacteremia events. The Centers for Medicare and Medicaid Services does not reimburse hospitals for costs incurred from preventable hospital-acquired complications. Consequently, hospital value-analysis committees increasingly view premium, infection-resistant peripheral catheters as strategic investments that insulate the health system from financial penalties and uncompensated inpatient stays.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation within the U.S. short peripheral intravenous catheter market has shifted from basic mechanical needle shielding toward comprehensive vascular access optimization platforms. Leading medical device manufacturers are developing systems that simplify clinical workflow, mitigate mechanical and chemical complications, preserve long-term peripheral venous capital, and facilitate auxiliary diagnostic functions such as needle-free diagnostic blood draws directly through the indwelling catheter.

Biomaterial engineering represents a central pillar of recent innovation. Early generations of peripheral catheters utilized rigid fluorinated ethylene propylene, which maintains mechanical column strength during skin puncture but remains stiff inside the vein, exerting chronic mechanical shear stress on fragile vascular endothelium and precipitating mechanical phlebitis. Modern advanced catheters are manufactured from proprietary medical-grade polyurethanes, such as Vialon biomaterial. These polyurethanes maintain column stiffness during initial skin and vessel penetration, but soften by up to 70% upon exposure to body temperature within the intravascular lumen. This thermal softening allows the cannula to conform to natural vessel tortuosity, reducing intraluminal irritation, endothelial stripping, and thrombosis, which directly supports prolonged clinical dwell times.

Multi-access blood-control septum engineering has eliminated the historical trade-offs associated with open-hub cannulation. Early blood-control valves operated as single-use barrier membranes that ruptured upon initial needle withdrawal, meaning subsequent line disconnections or syringe attachments risked blood leakage. Contemporary innovations utilize elastomeric multi-access septums capable of withstanding repeated luer connections and disconnections without loss of valve integrity. These septums mechanically seal against blood reflux until a male luer adapter is engaged, completely removing the requirement for clinicians to perform digital vein compression—a technique that is historically unreliable, technically challenging on deep veins, and a primary cause of cutaneous blood exposure.

The integration of diagnostic blood collection capabilities directly into short peripheral catheters represents another major technological leap. Historically, drawing blood specimens from an existing peripheral catheter resulted in high rates of red blood cell hemolysis, catheter lumen collapse under vacuum pressure, and contamination from intravenous fluids, forcing clinicians to perform separate, painful venipunctures for routine laboratory work. Recent technological platforms introduce specialized, micro-catheter blood-collection systems or dedicated push-button blood sampling pathways that navigate through the indwelling catheter lumen into the vein, drawing un-hemolyzed diagnostic blood samples without requiring an additional needle stick. By sparing patients an estimated three to five daily needle sticks during an inpatient stay, this technology protects peripheral veins, improves patient satisfaction scores, and saves considerable nursing and phlebotomy labor.

Vascular visualization integration has transformed catheter placement in patients with difficult vascular access. Manufacturers are engineering short peripheral catheters specifically designed for ultrasound-guided vascular access. These designs feature echogenic needle tips embedded with microscopic corner-cube reflectors or specialized surface texturing that reflects acoustic ultrasound waves back to the probe. Under bedside ultrasound, clinicians can track the needle tip in real time as it approaches deep brachial or basilic veins, reducing vessel wall overshoot, posterior wall puncture, and hematoma formation. Furthermore, manufacturers are extending the length of short peripheral catheters—producing 1.75-inch to 2.5-inch variants—to ensure that catheters placed in deeper veins maintain sufficient intravascular cannula length to prevent premature dislodgement and extravasation.

Catheter stabilization and securement platforms have evolved from external tape and transparent dressings into integrated engineering elements. Catheter-related micro-motion within the vein lumen is a leading contributor to mechanical phlebitis, endothelial trauma, and catheter dislodgement. Newer integrated catheter designs incorporate broad, flexible stabilization wings that contour to the anatomical curvature of the patient’s forearm or hand. These wings integrate with dedicated sutureless securement devices and engineered border dressings, locking the catheter hub into place and distributing external pulling forces across the skin rather than transferring mechanical stress directly to the intravascular cannula tip.

Passive safety shielding technology continues to advance, minimizing user dependency and eliminating human error. While active push-button safety mechanisms remain popular and offer tactile confirmation of retraction, passive safety technologies automatically encase the sharp needle tip within an internal protective housing or metal clip the instant the needle is withdrawn from the catheter hub. Because the passive mechanism activates without requiring an extra manual step or deliberate thumb action from the clinician, it provides fail-safe protection during sudden patient movements or emergency resuscitation scenarios, driving OSHA compliance and minimizing healthcare worker needlestick liability.

Segmentation Insights

The U.S. Short Peripheral Intravenous Catheters Market is segmented on the basis of product configuration, technology and safety mechanism, raw material, patient population and clinical application, end user, and geography.

By Product Configuration

The market is categorized into integrated and closed peripheral intravenous catheter systems, safety conventional open peripheral intravenous catheters, and non-safety conventional catheters.

Integrated / Closed Peripheral IV Catheters
Integrated and closed peripheral intravenous catheters represent the largest and fastest-growing product category, accounting for USD 1.28 billion in 2026, representing 57.40% of overall industry revenue. This segment expanded from USD 0.98 billion in 2023, USD 1.07 billion in 2024, and USD 1.17 billion in 2025, and is projected to reach USD 2.14 billion by 2032, advancing at a compound annual growth rate of 8.95% from 2027 through 2032.

The dominance of integrated systems is underpinned by their comprehensive design, which integrates the catheter cannula, pre-attached extension tubing, continuous stabilization platforms, and multi-access blood-control ports into a sealed unit. This pre-assembled configuration eliminates touch contamination risks associated with manually connecting external luer-lock extensions, while minimizing catheter manipulation and mechanical irritation within the vascular wall. Hospital clinical value analysis committees justify the premium unit price of integrated closed systems through demonstrable reductions in catheter dislodgement, accidental blood spillage, cutaneous blood exposure events, and premature catheter failure rates, allowing nursing teams to achieve longer in-situ dwell times while standardizing clinical insertion protocols across health networks.

Safety Conventional (Open) Peripheral IV Catheters
Safety conventional open peripheral intravenous catheters generated USD 0.87 billion in 2026, capturing 39.01% of market revenue, following historical revenues of USD 0.74 billion in 2023, USD 0.78 billion in 2024, and USD 0.82 billion in 2025. This segment is projected to achieve USD 1.22 billion by 2032, expanding at a CAGR of 5.79% across the forecast period.

Safety conventional catheters incorporate safety-engineered needle-retraction or needle-shielding mechanisms but lack integrated extension sets and pre-assembled closed fluid pathways, leaving the proximal hub open to the atmosphere until a separate extension set or intravenous line is manually attached. While conventional safety catheters remain popular across acute hospital floors, high-turnover emergency rooms, and budget-conscious community facilities due to their lower initial unit cost, their market share is gradually ceding ground to integrated systems as clinical protocols prioritize comprehensive blood containment and reduced hub-manipulation complications.

Non-Safety Conventional Peripheral IV Catheters
Non-safety conventional peripheral intravenous catheters accounted for USD 0.08 billion in 2026, representing 3.59% of total market value, declining from USD 0.10 billion in 2023, USD 0.09 billion in 2024, and USD 0.09 billion in 2025. This legacy segment is forecast to contract to USD 0.06 billion by 2032, registering a negative compound annual growth rate of -4.68% from 2027 to 2032.

The sustained contraction of non-safety catheters is a direct consequence of stringent regulatory enforcement under the OSHA Bloodborne Pathogens Standard and the federal Needlestick Safety and Prevention Act, which impose punitive institutional liabilities on healthcare facilities that utilize non-safety sharps when clinically effective safety alternatives exist. Utilization of non-safety devices in the United States is limited to highly specialized veterinary applications, laboratory animal research environments, and specific medical simulation training laboratories that operate outside standard human clinical care settings.

By Technology & Safety Mechanism

The market is segmented based on the engineering architecture of the safety mechanism into passive fully automatic safety catheters, active push-button manual shielding catheters, and non-safety standard catheters.

Passive / Fully Automatic Safety Catheters
Passive fully automatic safety peripheral intravenous catheters represented USD 1.29 billion in 2026, accounting for 57.85% of total market revenue. This technology segment expanded from USD 1.02 billion in 2023, USD 1.10 billion in 2024, and USD 1.19 billion in 2025, and is forecast to reach USD 2.09 billion by 2032, rising at a compound annual growth rate of 8.38% from 2027 through 2032.

Passive safety systems represent the gold standard in sharps safety compliance because their protective shielding mechanism triggers automatically during normal clinical extraction of the introducer needle, without requiring any deliberate manual action, button press, or thumb slide from the clinician. As the needle is withdrawn from the catheter hub, an engineered protective metal clip or internal spring immediately encases the beveled needle tip, permanently neutralizing the sharp. By removing the element of human compliance and operating reliably during chaotic clinical scenarios, such as combative patient movements in the emergency department or cardiac arrest resuscitations, passive safety catheters minimize accidental needlestick injuries and enjoy widespread preference across major enterprise health systems and academic hospital networks.

Active / Push-Button / Manual Shielding Safety Catheters
Active push-button and manual shielding safety peripheral intravenous catheters generated USD 0.86 billion in 2026, representing 38.56% of total market expenditure, after posting valuations of USD 0.70 billion in 2023, USD 0.75 billion in 2024, and USD 0.80 billion in 2025. This technology segment is projected to attain USD 1.27 billion by 2032, expanding at a CAGR of 6.72% over the forecast period.

Active safety catheters require the clinician to execute a deliberate physical step to activate the safety feature, such as depressing a push-button that instantly retracts the needle into a protective barrel, or manually advancing a protective plastic sheath over the needle shaft until it clicks into a locked position. Push-button retraction mechanisms maintain high nurse loyalty due to their instantaneous tactile and auditory confirmation of safety engagement, which provides peace of mind that the sharp is securely shielded before disposal. However, because active devices rely on deliberate user compliance, accidental needlesticks can occur if a clinician fails to activate the mechanism prior to disposal, slightly dampening long-term growth relative to passive architectures.

Non-Safety Conventional Technology
Non-safety conventional catheter technology accounted for USD 0.08 billion in 2026, reflecting 3.59% of market value, having generated USD 0.10 billion in 2023, USD 0.09 billion in 2024, and USD 0.09 billion in 2025. This segment will contract to USD 0.06 billion by 2032, decreasing at a -4.68% CAGR from 2027 to 2032.

The elimination of non-safety devices across United States healthcare facilities is nearly absolute, as risk management departments, hospital liability insurers, and clinical accreditation bodies mandate safety-engineered devices across all procedural areas. Continued sales are restricted to non-clinical applications and historical institutional inertia in small laboratory research centers that are exempt from OSHA clinical medical enforcement.

By Raw Material

The market is categorized by the primary polymer composition of the catheter cannula into polyurethane biomaterials and fluorinated ethylene propylene materials.

Polyurethane (PU) Biomaterials
Polyurethane biomaterials represent the clear commercial and clinical leader, capturing USD 1.76 billion in 2026, which translates to 78.92% of the U.S. market. The segment expanded from USD 1.40 billion in 2023, USD 1.51 billion in 2024, and USD 1.63 billion in 2025, and is projected to reach USD 2.80 billion by 2032, demonstrating a robust compound annual growth rate of 8.05% from 2027 through 2032.

The dominance of polyurethane stems from its thermoplastic characteristics and biocompatibility profile. Polyurethane cannulas exhibit high tensile strength and rigidity at room temperature, providing the column stiffness required to pierce the skin and penetrate the vessel wall without accordioning or peeling back. Upon entering the bloodstream and equilibrating with body temperature, the polyurethane polymer softens by 50% to 70%, transforming into a supple, flexible conduit that contours to natural venous tortuosity. This thermal softening drastically diminishes intraluminal shear stress and mechanical trauma against the vascular endothelium, resulting in significantly lower rates of mechanical phlebitis, intraluminal thrombus formation, and catheter extravasation. Polyurethane catheters are essential for clinical protocols targeting extended dwell times beyond 96 hours, making them the preferred biomaterial for acute care hospital networks.

Fluorinated Ethylene Propylene (FEP / Teflon)
Fluorinated ethylene propylene catheters accounted for USD 0.47 billion in 2026, representing 21.08% of market revenues, following historical levels of USD 0.42 billion in 2023, USD 0.43 billion in 2024, and USD 0.45 billion in 2025. This segment is expected to reach USD 0.62 billion by 2032, advancing at a modest CAGR of 4.73% across the forecast period.

FEP, historically known under the Teflon trade name, remains utilized due to its chemical inertness, high dielectric strength, and low friction coefficient, which allows smooth tissue transit during initial insertion. FEP maintains rigid column strength throughout its dwell time, making it useful in acute, short-duration applications such as emergency trauma resuscitations, rapid surgical inductions in ambulatory operating rooms, and single-dose diagnostic imaging contrast injections where immediate flow rate is critical and the catheter is slated for prompt removal within 12 to 24 hours. However, because FEP does not soften inside the vessel, its continuous mechanical stiffness causes higher rates of mechanical phlebitis and endothelial irritation if left in situ for extended periods, driving clinical preference toward polyurethane alternatives for multi-day inpatient stays.

By Patient Population & Clinical Application

The market is segmented based on the target clinical demographic and specialized procedural setting into adult inpatient and acute medical-surgical care, emergency and trauma resuscitation, pediatric and neonatal vascular access, and oncology and outpatient infusion therapy.

Adult Inpatient & Acute Medical-Surgical Care
Adult inpatient and acute medical-surgical care constitutes the largest clinical application, capturing USD 1.33 billion in 2026, which represents 59.64% of total market revenue. This segment grew from USD 1.09 billion in 2023, USD 1.16 billion in 2024, and USD 1.24 billion in 2025, and is projected to reach USD 2.01 billion by 2032, expanding at a compound annual growth rate of 7.12% from 2027 through 2032.

The sustained commercial scale of this application is driven by standard hospital protocols that require every admitted medical-surgical patient to have functional, patent venous access for baseline hydration, continuous intravenous medication delivery, electrolyte stabilization, and emergency pharmacology. Adult inpatient demographics are heavily weighted toward elderly patients with complex comorbid conditions—such as congestive heart failure, chronic obstructive pulmonary disease, and chronic renal impairment—which result in fragile, sclerotic, or non-visible peripheral veins. This clinical environment prioritizes catheters that support reliable first-stick success, reduce premature mechanical failure, and remain viable for the duration of typical 4- to 7-day inpatient admissions.

Emergency & Trauma Resuscitation
Emergency and trauma resuscitation applications generated USD 0.43 billion in 2026, accounting for 19.28% of overall market expenditure, following historical milestones of USD 0.35 billion in 2023, USD 0.37 billion in 2024, and USD 0.40 billion in 2025. This application segment is forecast to achieve USD 0.67 billion by 2032, growing at a CAGR of 7.68% across the forecast period.

Vascular access in emergency departments and pre-hospital trauma centers requires rapid cannulation under severe physiological stress. Clinicians in emergency medicine demand large-bore catheters—predominantly 14-gauge, 16-gauge, and 18-gauge variants—capable of delivering high-velocity fluid resuscitation, pressure-infused blood products, and rapid contrast administration for immediate computed tomography angiography. Emergency room procurement prioritizes catheters with sharp needle bevels for rapid flashback confirmation, ergonomic grip geometries that accommodate varying clinician insertion styles, and foolproof passive safety shielding that prevents accidental needlestick exposure during high-stress resuscitations involving uncooperative or crashing patients.

Pediatric & Neonatal Vascular Access
Pediatric and neonatal vascular access generated USD 0.28 billion in 2026, representing 12.56% of total market value, up from USD 0.22 billion in 2023, USD 0.24 billion in 2024, and USD 0.26 billion in 2025. This specialized application is projected to reach USD 0.45 billion by 2032, demonstrating a rapid CAGR of 8.23% from 2027 to 2032.

Pediatric and neonatal vascular cannulation represents one of the most technically demanding areas of nursing practice due to extremely small vessel calibers, low subcutaneous tissue support, and high physiological vulnerability. The pediatric segment requires dedicated micro-bore catheters—specifically 24-gauge and 26-gauge configurations—engineered with thin-walled cannulas that maximize internal lumen diameter to deliver adequate volumetric flow rates without hemolyzing infused fluids. Furthermore, pediatric lines incorporate specialized, gentle flash-back chambers capable of providing immediate visual blood confirmation upon minimal vessel entry, preventing clinicians from advancing the needle through the posterior vessel wall. Innovation in this space focuses on compact, lightweight catheter hubs that avoid placing excessive pressure on fragile neonatal skin, integrated stabilization wings that minimize skin tearing upon dressing removal, and ultra-soft polyurethane materials that protect small veins from mechanical inflammation.

Oncology & Outpatient Infusion Therapy
Oncology and outpatient infusion therapy accounted for USD 0.19 billion in 2026, representing 8.52% of market revenues, after generating USD 0.16 billion in 2023, USD 0.17 billion in 2024, and USD 0.18 billion in 2025. This segment is expected to reach USD 0.29 billion by 2032, rising at a compound annual growth rate of 7.31% over the forecast period.

The expansion of outpatient infusion suites is fueled by the clinical development of biological therapies, targeted immunotherapies, and monoclonal antibodies that are administered through scheduled outpatient infusions. Oncology patients frequently experience severe peripheral vascular depletion caused by repeated prior chemotherapy, toxic drug extravasation, and multiple blood samplings, resulting in fragile, scarred, and hyper-mobile veins. Outpatient infusion centers require high-precision peripheral catheters engineered to minimize mechanical friction and extravasation, as the accidental escape of vesicant antineoplastic drugs into subcutaneous tissue causes severe tissue necrosis and permanent nerve injury. The adoption of integrated closed catheters equipped with blood-control valves and extended-dwell capabilities allows outpatient infusion nurses to deliver targeted therapies safely while protecting the patient’s remaining venous access.

By End User

The market is categorized across primary healthcare purchasing environments into hospitals and integrated delivery networks, ambulatory surgery centers and outpatient clinics, emergency medical services and pre-hospital care, and long-term acute care and home infusion therapy providers.

Hospitals & Integrated Delivery Networks (IDNs)
Hospitals and integrated delivery networks constitute the principal commercial channel, accounting for USD 1.59 billion in 2026, or 71.30% of total industry revenue. This segment expanded from USD 1.31 billion in 2023, USD 1.39 billion in 2024, and USD 1.49 billion in 2025, and is projected to reach USD 2.41 billion by 2032, expanding at a 7.20% CAGR from 2027 through 2032.

The hospital market is defined by centralized corporate contracting, group purchasing organization alignment, and rigorous clinical value analysis. In an era of hospital consolidation, large integrated delivery networks negotiate multi-year enterprise contracts covering millions of catheter units across diverse hospital divisions, including emergency departments, intensive care units, perioperative suites, neonatal ICUs, and general medical-surgical floors. Hospital procurement leadership evaluates catheter portfolios through holistic clinical and financial models, balancing acquisition cost against clinical labor savings, complication rates, sharps safety compliance, and supply chain continuity. IDNs are standardizing their facilities around comprehensive integrated closed-system product lines to simplify clinical training, streamline inventory SKUs, and eliminate nursing practice variations across multi-facility health systems.

Ambulatory Surgery Centers (ASCs) & Outpatient Clinics
Ambulatory surgery centers and outpatient clinics generated USD 0.35 billion in 2026, representing 15.70% of total market revenue, following historical valuations of USD 0.27 billion in 2023, USD 0.29 billion in 2024, and USD 0.32 billion in 2025. This end-user segment represents the fastest-growing sector, forecast to reach USD 0.57 billion by 2032, advancing at a compound annual growth rate of 8.51% from 2027 to 2032.

The surge in outpatient surgical volume is driven by advancements in minimally invasive surgical techniques, refined anesthesia protocols, and payer incentives encouraging the migration of elective orthopedics, general surgery, and cardiovascular interventions from inpatient settings to ambulatory suites. ASCs operate on lean operating margins and high procedure-turnover models, demanding vascular access solutions that ensure fast, reliable cannulation during pre-operative intake to prevent surgical schedule delays. Outpatient clinics prioritize catheters that facilitate smooth vein entry, provide dependable flow rates for intravenous sedation, and feature integrated passive safety shielding to maintain clinical workplace safety in fast-paced outpatient procedural settings.

Emergency Medical Services (EMS) & Pre-Hospital Care
Emergency medical services and pre-hospital providers captured USD 0.17 billion in 2026, representing 7.62% of market expenditure, up from USD 0.14 billion in 2023, USD 0.15 billion in 2024, and USD 0.16 billion in 2025. The EMS segment is projected to achieve USD 0.26 billion by 2032, reflecting a compound annual growth rate of 7.34% across the forecast timeline.

Pre-hospital vascular access presents extreme environmental challenges, as paramedics and emergency medical technicians must cannulate hypovolemic, critically injured, or trapped patients in poorly lit, moving, or hostile environments. EMS agencies demand rugged, intuitive catheter systems packaged in durable, compact blister packs that withstand transport in emergency medical jump bags. Key requirements include rapid visual blood flashback confirmation, strong needle column stiffness to penetrate vasoconstricted veins, and robust passive needle shielding that protects paramedics from accidental needlesticks inside moving ambulances, where unexpected vehicle swerves or sudden patient movements create elevated sharps injury hazards.

Long-Term Acute Care & Home Infusion Therapy Providers
Long-term acute care facilities, skilled nursing centers, and home infusion therapy providers accounted for USD 0.12 billion in 2026, capturing 5.38% of market revenues, after generating USD 0.10 billion in 2023, USD 0.11 billion in 2024, and USD 0.11 billion in 2025. This segment is projected to reach USD 0.18 billion by 2032, expanding at a CAGR of 6.99% from 2027 through 2032.

This sector is supported by the transition of chronic, medically stable patients from acute hospital settings into specialized post-acute environments and home-based care for prolonged parenteral antibiotic courses, total parenteral nutrition, and palliative symptom management. Patients in long-term acute care facilities present with depleted peripheral vasculature and heightened vulnerability to catheter-related infections. Home infusion providers require catheters engineered for extended dwell longevity, featuring pre-assembled stabilization platforms and closed-system fluid pathways that reduce the risk of accidental dislodgement or hub contamination during routine activities in unmonitored home settings.

Regional Insights: Where the Market is Growing Fastest

The United States Short Peripheral Intravenous Catheters Market is segmented into four primary geographical divisions: the South, the Midwest, the Northeast, and the West. Regional demand profiles, commercial growth rates, and purchasing behaviors are shaped by population concentration, regional demographic aging trends, hospital bed capacity, group purchasing organization penetration, acute healthcare utilization rates, and the density of ambulatory surgical networks.

South

The Southern region represents the largest commercial market for short peripheral intravenous catheters in the United States, generating USD 0.86 billion in 2026, which constitutes 38.57% of total national revenue. The Southern market expanded from USD 0.69 billion in 2023, USD 0.74 billion in 2024, and USD 0.80 billion in 2025, and is projected to reach USD 1.34 billion by 2032, expanding at a compound annual growth rate of 7.68% from 2027 through 2032.

The dominance of the South is underpinned by rapid demographic expansion, massive net domestic migration, a dense concentration of Medicare beneficiaries, and expansive regional hospital systems. The Southern state cluster exhibits higher-than-average population rates of metabolic syndrome, diabetes, end-stage renal disease, and cardiovascular morbidity, which generate substantial acute inpatient admissions and a high clinical prevalence of difficult vascular access.

Texas represents the largest individual state market within the South and the second-largest nationally. Texas generated over USD 0.28 billion in peripheral catheter purchasing in 2026, anchored by world-class medical complexes such as the Texas Medical Center in Houston, along with massive health systems across Dallas-Fort Worth, San Antonio, and Austin. The continuous influx of corporate relocations and population growth has driven extensive hospital bed expansion and ambulatory surgery center construction, sustaining continuous demand for integrated closed catheter systems and specialized ultrasound-guided vascular access technologies.

Florida constitutes another critical commercial pillar within the Southern market, accounting for more than USD 0.22 billion in 2026 catheter procurement. Florida’s market is heavily influenced by its massive retiree population and Medicare-eligible demographic, which generates exceptional annual hospital inpatient admission volumes, high surgical procedural intensity, and elevated emergency department utilization. Elderly patients presenting across Florida health systems exhibit pronounced vascular fragility, driving clinical adoption of polyurethane catheters that soften inside the vein to minimize mechanical trauma, hematoma formation, and extravasation during extended hospitalizations.

North Carolina and Georgia provide substantial additional volume, generating USD 0.08 billion and USD 0.09 billion in 2026 catheter revenue, respectively. North Carolina benefits from the concentration of advanced academic health networks across the Research Triangle, Charlotte, and Winston-Salem, where hospital value analysis committees demonstrate early clinical adoption of advanced blood-control catheters and needle-free blood sampling systems. Georgia’s vascular access purchasing is anchored by massive integrated health systems and regional trauma centers in metropolitan Atlanta, which process high volumes of acute medical and surgical patients. Tennessee, Virginia, Louisiana, Alabama, and South Carolina add significant volume, characterized by large rural and suburban hospital networks that procure safety catheters through centralized group purchasing organization agreements. The operational priority across Southern health systems is managing high patient throughput while mitigating the clinical labor impact of the nursing shortage through high first-stick success catheters.

Midwest

The Midwestern region represents a stable, high-volume market, generating USD 0.50 billion in 2026, which represents 22.42% of total national expenditure. The Midwest posted revenues of USD 0.42 billion in 2023, USD 0.44 billion in 2024, and USD 0.47 billion in 2025, and is forecast to achieve USD 0.75 billion by 2032, rising at a compound annual growth rate of 6.99% across the forecast period.

The Midwest is characterized by high hospital bed-to-population ratios, an aging industrial workforce with elevated rates of chronic cardiopulmonary and metabolic disease, and mature integrated delivery networks with sophisticated clinical standardization protocols.

Ohio represents the leading state market in the Midwest, capturing USD 0.12 billion in 2026 catheter revenue. Ohio is home to internationally renowned health systems, including the Cleveland Clinic and OhioHealth, which maintain rigorous vascular access protocols and lead clinical research in peripheral line complication reduction. These institutions serve as benchmark evaluators for innovative catheter biomaterials, passive needle safety technologies, and closed systems that prevent occupational blood contact.

Illinois follows closely, generating USD 0.11 billion in 2026, driven by the concentration of major academic medical centers and sprawling hospital networks throughout the Chicago metropolitan area. Illinois health systems maintain aggressive vascular access quality improvement programs, tracking peripheral line-associated complications and standardizing supply chain purchasing around integrated closed-system catheter platforms.

Michigan generated USD 0.09 billion in 2026, with procurement centered across massive hospital systems in Detroit, Ann Arbor, and Grand Rapids. Clinical teams in Michigan academic centers have contributed extensively to national vascular access literature, driving institutional adoption of ultrasound-guided deep peripheral access lines for difficult vascular access patients.

Indiana, Wisconsin, Minnesota, and Missouri contribute vital volume to the Midwestern total. Minnesota is distinguished by its dense medical technology ecosystem and the presence of world-class healthcare institutions like the Mayo Clinic, which prioritize advanced clinical technologies that enhance patient safety and nursing efficiency. Across the Midwest, procurement is heavily consolidated through national group purchasing organizations, with hospital value analysis committees focusing on clinical evidence that links advanced catheter adoption to reduced overall hospital costs, shorter venipuncture placement times, and lower rates of premature catheter restarts.

Northeast

The Northeastern region accounted for USD 0.46 billion in 2026, representing 20.63% of the U.S. short peripheral intravenous catheter market. The region grew from USD 0.38 billion in 2023, USD 0.40 billion in 2024, and USD 0.43 billion in 2025, and is projected to reach USD 0.69 billion by 2032, expanding at a CAGR of 6.98% from 2027 to 2032.

Although the Northeast is geographically smaller than other regions, it exhibits the highest concentration of elite academic medical centers, tertiary research hospitals, specialized cancer institutes, and prestigious pediatric health systems in the nation. Procurement in the Northeast is characterized by an evidence-based clinical culture that willingly pays a premium for advanced medical device technologies that demonstrate clinical superiority, rigorous infection prevention, and occupational safety.

New York is the dominant state market in the Northeast, generating USD 0.17 billion in 2026 catheter purchasing. New York City represents one of the densest healthcare markets in the world, featuring massive municipal hospital systems and renowned academic health networks that place millions of peripheral catheters annually. High patient turnover in emergency departments and intensive surgical procedural volumes across Manhattan, Brooklyn, and Long Island drive strong demand for integrated closed catheters with multi-access blood-control septums that minimize cutaneous blood exposure and streamline bedside nursing workflow.

Pennsylvania represents the second-largest Northeastern state market, generating USD 0.12 billion in 2026, anchored by large health systems across Philadelphia and Pittsburgh. Pennsylvania hospitals maintain progressive vascular access specialist teams that advocate for the institutional adoption of extended-dwell polyurethane catheters and specialized lines for difficult vascular access populations.

Massachusetts accounted for USD 0.07 billion in 2026, exerting clinical and intellectual influence out of proportion to its physical size. Centered around the Boston academic healthcare and biomedical research cluster, Massachusetts hospitals serve as primary testing sites for next-generation vascular access technologies, including needle-free blood sampling catheter attachments, advanced echogenic coatings for ultrasound placement, and automated sharps safety platforms.

New Jersey, Connecticut, Rhode Island, Maine, New Hampshire, and Vermont contribute significant additional volume, characterized by sophisticated community hospital networks and expanding ambulatory surgery center ecosystems. Healthcare institutions in the Northeast demonstrate low tolerance for occupational sharps injuries and hospital-acquired infections, driving high institutional penetration of premium passive safety mechanisms and integrated closed catheter architectures.

West

The Western region represents the fastest-growing geographical market for short peripheral intravenous catheters, generating USD 0.41 billion in 2026, or 18.38% of total U.S. market value. The West advanced from USD 0.33 billion in 2023, USD 0.36 billion in 2024, and USD 0.38 billion in 2025, and is projected to attain USD 0.64 billion by 2032, demonstrating a market-leading compound annual growth rate of 7.71% over the forecast period.

Growth across the West is propelled by rapid population expansion in Mountain West states, an expanding network of technologically progressive health systems, early institutional adoption of digital and ultrasound-guided clinical workflows, and the rapid migration of elective surgeries to ambulatory surgery centers.

California dominates the Western market by volume and revenue, capturing USD 0.21 billion in 2026, which represents over half of the entire Western regional market. California represents the largest state healthcare economy in the United States, distinguished by massive integrated health systems such as Kaiser Permanente, Sutter Health, Dignity Health, and academic health systems across the University of California network. California was the pioneer in establishing rigid legislative workplace safety standards governing needlestick prevention, establishing a regulatory climate that demands the highest tier of passive safety-engineered vascular access devices. Furthermore, the state’s progressive approach to ambulatory care and outpatient surgery drives high demand for integrated catheters that deliver reliable first-stick success, low complication rates, and rapid procedural turnover.

Washington state represents the second-largest Western market, generating USD 0.05 billion in 2026, centered on the Seattle metropolitan healthcare and technology corridor. Washington health systems lead in the clinical implementation of ultrasound-guided vascular access programs, driving demand for specialized echogenic long-peripheral catheters designed for deep vessel cannulation.

Arizona accounted for USD 0.04 billion in 2026, registering high growth driven by substantial in-migration of retirees and rapid expansion of hospital bed capacity throughout Phoenix, Scottsdale, and Tucson. The influx of elderly patients with complex vascular anatomy creates a robust commercial market for thermo-softening polyurethane catheters that maintain dwell integrity in fragile veins.

Colorado, Oregon, Nevada, Utah, Idaho, New Mexico, and the remaining Western states contribute vital recurring volume. States such as Utah and Colorado are experiencing robust economic and population growth, accompanied by modern hospital construction and the expansion of suburban ambulatory surgical networks. Healthcare buyers across the Western region prioritize clinical efficiency, innovative device features, and workflow-integrated solutions that allow nursing personnel to achieve vascular access reliably while minimizing procedural complications and occupational hazards.

Key Market Players

The U.S. Short Peripheral Intravenous Catheters competitive landscape is highly consolidated at the top tier around a small number of global medical technology corporations that command dominant market shares through extensive intellectual property portfolios, massive automated manufacturing infrastructure, established brand equity, and multi-year corporate contracts with major national group purchasing organizations. However, specialized medtech manufacturers, vascular access innovators, and large private-label healthcare distributors maintain critical market presence across niche clinical segments, including ultrasound-guided deep vein access, specialized pediatric systems, active push-button devices, and cost-effective community hospital supply lines.

The highly relevant players operating in the U.S. short peripheral intravenous catheters market are:

Becton, Dickinson and Company (BD)
B. Braun Melsungen AG / B. Braun Medical Inc.
ICU Medical, Inc.
Teleflex Incorporated
Terumo Corporation / Terumo Medical Corporation
Argon Medical Devices, Inc.
NIPRO Corporation / NIPRO Medical USA
Merit Medical Systems, Inc.
Vygon SA / Vygon USA
Retractable Technologies, Inc.
AngioDynamics, Inc.
Medline Industries, LP
Greiner Bio-One International GmbH
Cardinal Health, Inc.
Cook Medical LLC

Becton, Dickinson and Company (BD) occupies the undisputed market leadership position within the United States, commanding dominant market share across acute care hospitals, emergency departments, and ambulatory networks. BD’s vascular access portfolio is anchored by its flagship BD Insyte Autoguard BC shielded peripheral IV catheter and the BD Nexiva closed IV catheter system. The Insyte Autoguard platform features push-button needle retraction technology combined with proprietary Vialon biomaterial, which softens intravascularly to minimize mechanical phlebitis. BD’s Nexiva platform pioneered the integrated closed-catheter market, combining an all-in-one pre-assembled system with a multi-access blood-control septum, stabilization platform, and integrated extension tubing. BD has extended its leadership through the development of the BD PIV5C catheter, engineered specifically to support needle-free diagnostic blood draws directly from the indwelling peripheral line, transforming the catheter from a simple infusion portal into a multi-functional diagnostic and therapeutic platform.

B. Braun Medical Inc. represents another major force in the U.S. vascular access market, competing aggressively across acute hospital systems, ambulatory surgery centers, and alternate-site infusion providers. B. Braun’s primary market offering is the Introcan Safety family of peripheral catheters, which features passive safety shielding technology that automatically engages upon needle withdrawal without requiring active user manipulation. The company’s Introcan Safety 2 and Introcan Safety Deep Access platforms incorporate multi-access blood-control septums that eliminate blood leakage during insertion and subsequent hub connections, alongside specialized longer-length polyurethane catheters designed specifically for ultrasound-guided deep vein placement in difficult vascular access patients. B. Braun leverages strong environmental sustainability initiatives and PVC-free, DEHP-free manufacturing standards to appeal to hospital sustainability committees.

ICU Medical, Inc., following its landmark acquisition of Smiths Medical, commands a massive installed base across United States health systems. The company’s portfolio includes the renowned Jelco family of peripheral catheters, featuring the Jelco IntuitIV Safety IV Catheter, the ViaValve Safety IV Catheter, and the AccuCath Ace intravascular catheter system. ICU Medical’s ViaValve technology incorporates blood-control valves that minimize blood exposure during insertion, while the AccuCath platform utilizes specialized coiled-tip guide wire technology designed to facilitate smooth catheter advancement into fragile, tortuous, or deep veins, significantly improving first-stick cannulation success in challenging inpatient cohorts. ICU Medical maintains deep corporate contracting relationships with national group purchasing organizations and integrated delivery networks.

Teleflex Incorporated competes in the premium tier of the vascular access market, leveraging its renowned Arrow brand to deliver advanced vascular access solutions. While historically dominant in central venous catheters and peripherally inserted central catheters, Teleflex has expanded its presence in the short and mid-length peripheral catheter sector with products such as the Arrow QuickFlash Radial Artery/Peripheral Catheter and specialized extended-dwell peripheral lines. Teleflex focuses on high-acuity clinical environments, including intensive care units, trauma resuscitations, and emergency departments, offering catheters engineered with advanced polyurethane biomaterials, precision needle bevels, and integrated guide wires that assist in navigating compromised patient vasculature.

Terumo Medical Corporation maintains a strong presence across hospital operating rooms, interventional suites, and emergency departments through its Surflo and Surshield product lines. Terumo is recognized for manufacturing needle bevels with exceptional sharpness, utilizing proprietary double-bevel grinding technology that minimizes tissue resistance and patient pain during initial skin puncture. The Surshield Safety IV Catheter incorporates an active, hinged needle-shielding mechanism that allows clinicians to lock the protective sheath over the sharp needle with a single finger, providing straightforward safety compliance in fast-paced surgical and outpatient procedural settings.

Argon Medical Devices focuses on specialized vascular access and interventional procedural products. Argon supplies acute care facilities with high-performance catheter systems designed for reliable fluid delivery, contrast administration, and specialized diagnostic access, leveraging precision manufacturing to serve tertiary hospital systems and specialized radiology clinics.

NIPRO Medical USA, a subsidiary of Japan-based NIPRO Corporation, supplies a growing portfolio of conventional and safety peripheral IV catheters to American hospital networks, dialysis centers, and alternate-site infusion clinics. NIPRO differentiates its commercial offering through precision needle manufacturing, smooth silicone coating technologies that reduce insertion drag, and competitive economic pricing models that appeal to cost-conscious community hospital networks and high-volume outpatient clinics.

Merit Medical Systems specializes in medical devices used in interventional cardiology, radiology, and oncology suites. Merit provides specialized peripheral access devices and micro-access kits engineered for precision vascular entry, catering to clinicians who perform complex peripheral catheterizations and contrast delivery during image-guided diagnostic and therapeutic procedures.

Vygon USA provides specialized vascular access lines tailored to pediatric, neonatal, and high-acuity critical care applications. Vygon’s portfolio includes micro-bore peripheral catheters engineered to deliver precise flow rates in extremely low-birth-weight infants without causing vessel wall rupture or endothelial trauma, making the company a trusted partner for neonatal intensive care units across the country.

Retractable Technologies, Inc. is an American innovator dedicated exclusively to sharps injury prevention. The company manufactures the VanishPoint safety IV catheter, which utilizes automated spring-loaded retraction technology. Upon depression of the activation collar, the introducer needle instantly retracts from the patient’s vein directly into the catheter body, virtually eliminating exposure to the contaminated sharp. Retractable Technologies maintains contracts with federal healthcare systems, Veterans Affairs hospitals, and public health networks that prioritize occupational worker safety.

AngioDynamics, Inc. participates in the vascular access market through specialized peripheral access and mid-length catheter technologies. The company focuses on vascular access solutions that bridge the gap between standard short peripheral catheters and invasive central lines, offering advanced materials that resist intraluminal occlusion and thrombosis during extended hospital stays.

Medline Industries, LP operates as both a leading manufacturer and the largest private medical-surgical distributor in the United States. Medline markets its own branded lines of safety peripheral catheters, including the Maxguard and Safelet product lines, alongside comprehensive custom vascular access procedural kits and trays. Medline’s competitive strength lies in its unmatched supply chain logistics, direct distribution infrastructure, and ability to bundle peripheral catheters with complete skin antisepsis, stabilization dressings, and intravenous start kits at aggressive pricing for integrated health systems and long-term care networks.

Greiner Bio-One International GmbH provides high-precision vascular access and blood collection safety products, offering specialized peripheral catheter systems that integrate seamlessly with vacuum blood-collection tubes, supporting combined infusion and diagnostic sampling protocols across outpatient clinics and acute facilities.

Cardinal Health, Inc. operates an expansive healthcare distribution and manufacturing enterprise, supplying health systems nationwide with private-label and branded safety peripheral IV catheters. Cardinal Health leverages its deep supply chain integration to deliver standardized, cost-effective peripheral catheter lines bundled into customized IV start kits for acute care hospitals, ambulatory surgery centers, and government healthcare facilities.

Cook Medical LLC maintains a specialized focus in minimally invasive vascular access, providing precision-engineered peripheral access sets, introducers, and specialized catheter lines utilizing advanced wire-guided techniques to achieve vascular entry in patients with anatomically compromised or difficult peripheral veins.

Competitive advantage across the forecast period will depend on manufacturing automation, intellectual property protection around blood-control septums and passive needle-shielding mechanisms, supply chain resilience, and the strategic ability to offer comprehensive vascular access ecosystems that integrate insertion devices, visualization guidance, catheter securement, and diagnostic blood sampling capabilities.

Recent Developments

The United States short peripheral intravenous catheter landscape has experienced substantial clinical, regulatory, and commercial evolution, reshaping device design and hospital procurement protocols.

A primary development is the clinical integration of blood-drawing capabilities into standard indwelling peripheral intravenous catheters. Historically, collecting diagnostic blood samples from a peripheral line resulted in catastrophic hemolysis rates and collapsed catheter walls, forcing phlebotomists and nurses to perform separate, painful venipunctures multiple times per day. The commercial introduction and rapid health-system adoption of specialized closed catheters equipped with internal blood-draw pathways—such as the BD PIV5C platform and needle-free blood sampling access systems—allow clinical teams to draw pure, un-hemolyzed diagnostic blood specimens directly through the existing peripheral catheter. Health systems adopting this technology report major reductions in patient needle sticks, dramatic declines in sample hemolysis-induced laboratory redraws, and substantial labor time savings for bedside nursing staff.

The regulatory and clinical oversight surrounding peripheral catheter complications has intensified. While central line-associated bloodstream infections have long been tracked under national quality metrics, clinical research institutions and healthcare quality agencies are focusing on the incidence of peripheral line-associated bloodstream infections. Epidemiological surveillance indicates that because hundreds of millions of peripheral lines are placed annually, the absolute number of peripheral line bacteremia events rivals central line infections. Consequently, hospital value-analysis committees are mandating the adoption of all-in-one integrated closed catheters equipped with multi-access septums that eliminate blood leakage and minimize touch contamination at the hub, directly supporting institutional zero-infection campaigns.

The widespread clinical adoption of bedside ultrasound guidance for peripheral vascular access has altered catheter length and design requirements. Historically, clinicians placed standard 1-inch to 1.25-inch catheters in superficial veins of the hand or forearm using tactile palpation. In modern acute care settings, up to 40% of patients require ultrasound guidance to identify deeper veins, such as the cephalic, basilic, or brachial veins located 1 to 2 centimeters beneath the skin. When standard-length catheters are placed in deep vessels, only a small portion of the cannula resides within the vein lumen, leading to premature dislodgement and extravasation when the patient bends their arm. Manufacturers have responded by securing FDA 510(k) clearances for specialized deep-access peripheral catheters featuring 1.75-inch to 2.5-inch cannulas and micro-textured echogenic needle tips that provide bright acoustic reflection under ultrasound visualization, improving first-stick success in difficult vascular access cohorts.

Supply chain diversification and domestic automated manufacturing investments have accelerated across major medtech competitors. Global supply chain disruptions and raw material shortages experienced in recent years highlighted vulnerabilities in offshore catheter assembly. In response, leading medical device manufacturers have invested hundreds of millions of dollars into high-speed, fully automated, robotics-driven manufacturing lines within the United States and North America. Automated production ensures micro-tolerances during needle grinding, catheter tip tipping, and lubricious silicone coating application, while eliminating human contact during assembly, improving product quality, and insulating American health systems from international shipping bottlenecks.

The formal update and implementation of the Infusion Nurses Society Infusion Therapy Standards of Practice has reinforced the shift from arbitrary time-based catheter restarts to clinically indicated removal protocols. The standards state that peripheral catheters should not be removed based on arbitrary 72- or 96-hour deadlines, but should remain in place until the completion of therapy unless a clinical complication arises. This regulatory guideline has focused hospital purchasing committees on catheter durability, biocompatibility, and advanced biomaterials that resist thrombosis and intraluminal occlusion, driving the transition from rigid fluorinated ethylene propylene toward soft, thermo-responsive polyurethane formulations.

Enterprise-level hospital group purchasing organization contracting has shifted toward comprehensive vascular access bundle solutions. Health systems are rejecting piecemeal purchasing of disparate needles, extension sets, securement dressings, and skin antiseptics from multiple separate vendors. Instead, major GPOs, such as Vizient, Premier, and HealthTrust, are awarding comprehensive long-term sole-source and dual-source contracts to manufacturers capable of supplying standardized vascular access bundles. These bundles encompass the peripheral catheter, chlorhexidine gluconate skin preparation, engineered sutureless stabilization devices, antimicrobial transparent dressings, and passive disinfection caps, providing standardized clinical workflows that lower overall procedural costs and decrease clinical variation across large health networks.

Conclusion

The U.S. Short Peripheral Intravenous Catheters Market is positioned for robust capital expansion, scaling from USD 2.23 billion in 2026 to approximately USD 3.42 billion by 2032, propelled by a 7.39% compound annual growth rate across the forecast period. The historical market development from USD 1.82 billion in 2023 to USD 2.08 billion in 2025 demonstrates the steady normalization of inpatient hospital admissions, the rapid expansion of ambulatory surgery centers, and the decisive institutional shift toward advanced, safety-engineered vascular access platforms.

The commercial growth story within the U.S. peripheral catheter industry extends far beyond simple volume increases driven by population growth. The market is undergoing a structural paradigm shift in device architecture and clinical workflow economics. Healthcare delivery networks are actively retiring low-cost, open-system conventional safety catheters in favor of fully integrated, closed-system catheter architectures equipped with multi-access blood-control septums, advanced polyurethane biomaterials, and integrated stabilization platforms. Although integrated closed systems command higher initial unit acquisition costs, hospital value-analysis committees, chief medical officers, and nursing executives recognize that they generate substantial net financial savings by preventing occupational blood exposures, lowering first-stick insertion failure rates, eliminating secondary assembly supplies, reducing premature catheter dislodgement, and mitigating catheter-related bloodstream infections.

Product configuration dynamics will continue to favor integrated closed systems, which are projected to capture USD 2.14 billion by 2032, expanding at an 8.95% CAGR and accounting for 62.57% of total market revenue. Safety technology will remain dominated by passive, fully automatic shielding mechanisms that guarantee OSHA compliance and protect clinicians without requiring active physical manipulation during emergency scenarios. Biomaterial selection will increasingly center on thermo-softening polyurethanes that soften inside the bloodstream to protect delicate endothelial tissue and support extended dwell times beyond 5 to 7 days, aligning with clinically indicated catheter replacement protocols.

Geographically, the South will maintain its position as the largest commercial market, scaling to USD 1.34 billion by 2032, sustained by massive demographic expansion, high Medicare patient density, and extensive hospital infrastructure across Texas, Florida, North Carolina, and Georgia. The West will achieve the fastest regional expansion, rising at a 7.71% CAGR to reach USD 0.64 billion by 2032, driven by technologically advanced hospital systems and the rapid migration of surgical procedures to ambulatory surgical centers in California, Washington, and Arizona. The Northeast and Midwest will provide durable, multi-million-dollar revenue streams anchored by prestigious academic medical centers and highly standardized integrated delivery networks.

For medical device manufacturers, clinical leadership, hospital supply chain executives, and healthcare investors, competitive success through 2032 will belong to organizations that deliver integrated vascular access ecosystems. Companies that integrate high-precision echogenic needle visibility for ultrasound-guided deep vein access, multi-access blood containment valves, durable thermo-softening polymers, and needle-free diagnostic blood collection capabilities will capture market share. By aligning medical device innovation with bedside nursing efficiency, institutional infection prevention, and the protection of long-term patient vascular capital, the short peripheral intravenous catheter industry is establishing the gold standard for clinical safety and operational economics in American acute healthcare.